Effect of far infrared therapy on arteriovenous fistula maturation, survival and stenosis in hemodialysis patients, a randomized, controlled clinical trial: the FAITH on fistula trial

K Lindhard, M Rix, J G Heaf, H P Hansen, B L Pedersen, B L Jensen, D Hansen, K Lindhard, M Rix, J G Heaf, H P Hansen, B L Pedersen, B L Jensen, D Hansen

Abstract

Background: An arteriovenous fistula (AVF) is the preferred vascular access for hemodialysis treatment. After creation many of the AVFs will never mature or if functioning will need an intervention within 1 year due to an AVF stenosis. Studies investigating possible therapies that improves the AVF maturation and survival are scarce. Far infrared therapy (FIR) has shown promising results. In minor single centre and industry supported trials FIR has shown improved AVF maturation and survival. There is a need of a randomized multicentre controlled trial to examine the effect of FIR on the AVF maturation and survival and to explore the possible AVF protective mechanism induced by the FIR treatment.

Methods: This investigator initiated, randomized, controlled, open-labeled, multicenter clinical trial will examine the effect of FIR on AVF maturation in patients with a newly created AVF (incident) and AVF patency rate after 1 year of treatment in patients with an existing AVF (prevalent) compared to a control group. The intervention group will receive FIR to the skin above their AVF three times a week for 1 year. The control group will be observed without any treatment. The primary outcome for incident AVFs is the time from surgically creation of the AVF to successful cannulation. The primary outcome for the prevalent AVFs is the difference in number of AVFs without intervention and still functioning in the treatment and control group after 12 months. Furthermore, the acute changes in inflammatory and vasodilating factors during FIR will be explored. Arterial stiffness as a marker of long term AVF patency will also be examined.

Discussion: FIR is a promising new treatment modality that may potentially lead to improved AVF maturation and survival. This randomized controlled open-labelled trial will investigate the effect of FIR and its possible mechanisms.

Trial registration: Clinicaltrialsgov NCT04011072 (7th of July 2019).

Keywords: AVF maturation; AVF patency; Arteriovenous fistula; Hemodialysis; Infrared therapy.

Conflict of interest statement

The authors declares that they have no competing interest. All the funding agencies did not have any role in the development of the study, study design, data collection, analysing and preparation of the manuscript for publication.

© 2021. The Author(s).

Figures

Fig. 1
Fig. 1
Study design and participants
Fig. 2
Fig. 2
Picture of a enrolled patient receiving FIR treatment on his arteriovenous fistula (informed consent is given)

References

    1. Thomas B, Wulf S, Bikbov B, Perico N, Cortinovis M, De Vaccaro KC, et al. Maintenance dialysis throughout the world in years 1990 and 2010. J Am Soc Nephrol. 2015;26(11):2621–2633. doi: 10.1681/ASN.2014101017.
    1. Schmidli J, Widmer MK, Basile C, de Donato G, Gallieni M, Gibbons CP, Haage P, Hamilton G, Hedin U, Kamper L, Lazarides MK, Lindsey B, Mestres G, Pegoraro M, Roy J, Setacci C, Shemesh D, Tordoir JHM, van Loon M, ESVS Guidelines Committee, Kolh P, de Borst GJ, Chakfe N, Debus S, Hinchliffe R, Kakkos S, Koncar I, Lindholt J, Naylor R, Vega de Ceniga M, Vermassen F, Verzini F, ESVS Guidelines Reviewers, Mohaupt M, Ricco JB, Roca-Tey R. Editor’s choice – vascular access: 2018 clinical practice guidelines of the European Society for Vascular Surgery (ESVS) Eur J Vasc Endovasc Surg. 2018;55(6):757–818. doi: 10.1016/j.ejvs.2018.02.001.
    1. Lok CE, Huber TS, Lee T, Shenoy S, Yevzlin AS, Abreo K, et al. KDOQI Clinical Practice Guideline for Vascular Access. Am J Kidney Dis. 2020;75(4):S1–164.
    1. Bray BD, Boyd J, Daly C, Donaldson K, Doyle A, Fox JG, Innes A, Khan I, Peel RK, Severn A, Shilliday I, Simpson K, Stewart GA, Traynor J, Metcalfe W, on behalf of the Scottish Renal Registry Vascular access type and risk of mortality in a national prospective cohort of haemodialysis patients. Qjm. 2012;105(11):1097–1103. doi: 10.1093/qjmed/hcs143.
    1. Vassalotti JA, Jennings WC, Beathard GA, Neumann M, Caponi S, Fox CH, Spergel LM, the Fistula First Breakthrough Initiative Community Education Committee Fistula first breakthrough initiative: targeting catheter last in fistula first. Semin Dial. 2012;25(3):303–310. doi: 10.1111/j.1525-139X.2012.01069.x.
    1. Dhingra RK, Young EW, Hulbert-Shearon TE, Leavey SF, Port FK. Type of vascular access and mortality in U.S. hemodialysis patients. Kidney Int. 2001;60(4):1443–1451. doi: 10.1046/j.1523-1755.2001.00947.x.
    1. Lacson E, Wang W, Hakim RM, Teng M, Lazarus JM. Associates of Mortality and Hospitalization in hemodialysis: potentially actionable laboratory variables and vascular access. Am J Kidney Dis. 2009;53(1):79–90. doi: 10.1053/j.ajkd.2008.07.031.
    1. Murad MH, Elamin MB, Sidawy AN, Malaga G, Rizvi AZ, Flynn DN, et al. Autogenous versus prosthetic vascular access for hemodialysis: a systematic review and meta-analysis. J Vasc Surg. 2008;48(5 SUPPL):34–47. doi: 10.1016/j.jvs.2008.08.044.
    1. Almasri J, Alsawas M, Mainou M, Mustafa RA, Wang Z, Woo K, Cull DL, Murad MH. Outcomes of vascular access for hemodialysis: a systematic review and meta-analysis. J Vasc Surg. 2016;64(1):236–243. doi: 10.1016/j.jvs.2016.01.053.
    1. Al-Jaishi AA, Oliver MJ, Thomas SM, Lok CE, Zhang JC, Garg AX, et al. Patency rates of the arteriovenous fistula for hemodialysis: a systematic review and meta-analysis. Am J Kidney Dis. 2014;63(3):464–478. doi: 10.1053/j.ajkd.2013.08.023.
    1. Lok CE, Sontrop JM, Tomlinson G, Rajan D, Cattral M, Oreopoulos G, Harris J, Moist L. Cumulative patency of contemporary fistulas versus grafts (2000-2010) Clin J Am Soc Nephrol. 2013;8(5):810–818. doi: 10.2215/CJN.00730112.
    1. Bashar K, Conlon PJ, Kheirelseid EAH, Aherne T, Walsh SR, Leahy A. Arteriovenous fistula in dialysis patients: factors implicated in early and late AVF maturation failure. Surgeon. 2016;14(5):294–300. doi: 10.1016/j.surge.2016.02.001.
    1. Smith GE, Gohil R, Chetter IC. Factors affecting the patency of arteriovenous fistulas for dialysis access. J Vasc Surg. 2012;55(3):849–855. doi: 10.1016/j.jvs.2011.07.095.
    1. Rayner HC, Pisoni RL, Gillespie BW, Goodkin DA, Akiba T, Akizawa T, Saito A, Young EW, Port FK, Dialysis Outcomes and Practice Patterns Study Creation, cannulation and survival of arteriovenous fistulae: data from the dialysis outcomes and practice patterns study. Kidney Int. 2003;63(1):323–330. doi: 10.1046/j.1523-1755.2003.00724.x.
    1. Lauvao LS, Ihnat DM, Goshima KR, Chavez LA, Gruessner AC, Mills JL. Vein diameter is the major predictor of fistula maturation. J Vasc Surg. 2009;49(6):1499–1504. doi: 10.1016/j.jvs.2009.02.018.
    1. Roy-Chaudhury P, Sukhatme VP, Cheung AK. Hemodialysis vascular access dysfunction: a cellular and molecular viewpoint. J Am Soc Nephrol. 2006;17(4):1112–1127. doi: 10.1681/ASN.2005050615.
    1. Lee T, Haq NU. New developments in our understanding of Neointimal hyperplasia. Adv Chronic Kidney Dis. 2015;22(6):431–437. doi: 10.1053/j.ackd.2015.06.010.
    1. Gallieni M, Hollenbeck M, Inston N, Kumwenda M, Powell S, Tordoir J, al Shakarchi J, Berger P, Bolignano D, Cassidy D, Chan TY, Dhondt A, Drechsler C, Ecder T, Finocchiaro P, Haller M, Hanko J, Heye S, Ibeas J, Jemcov T, Kershaw S, Khawaja A, Labriola L, Lomonte C, Malovrh M, Monros AMI, Matthew S, McGrogan D, Meyer T, Mikros S, Nistor I, Planken N, Roca-Tey R, Ross R, Troxler M, van der Veer S, Vanholder R, Vermassen F, Welander G, Wilmink T, Koobasi M, Fox J, van Biesen W, Nagler E. Clinical practice guideline on peri- and postoperative care of arteriovenous fistulas and grafts for haemodialysis in adults. Nephrol Dial Transplant. 2019;34(Supplement_2):II1–I42. doi: 10.1093/ndt/gfz072.
    1. Ikeda Y, Biro S, Kamogawa Y, Yoshifuku S, Eto H, Orihara K, Yu B, Kihara T, Miyata M, Hamasaki S, Otsuji Y, Minagoe S, Tei C. Repeated sauna therapy increases arterial endothelial nitric oxide synthase expression and nitric oxide production in cardiomyopathic hamsters. Circ J. 2005;69(6):722–729. doi: 10.1253/circj.69.722.
    1. Shui S, Wang X, Chiang JY, Zheng L. Far-infrared therapy for cardiovascular, autoimmune, and other chronic health problems: a systematic review. Exp Biol Med. 2015;240(10):1257–1265. doi: 10.1177/1535370215573391.
    1. Lin CC, Liu XM, Peyton K, Wang H, Yang WC, Lin SJ, Durante W. Far infrared therapy inhibits vascular endothelial inflammation via the induction of heme oxygenase-1. Arterioscler Thromb Vasc Biol. 2008;28(4):739–745. doi: 10.1161/ATVBAHA.107.160085.
    1. Lin CC, Yang WC, Chen MC, Liu WS, Yang CY, Lee PC. Effect of far infrared therapy on arteriovenous fistula maturation: an open-label randomized controlled trial. Am J Kidney Dis. 2013;62(2):304–311. doi: 10.1053/j.ajkd.2013.01.015.
    1. Lin CC, Chang CF, Lai MY, Chen TW, Lee PC, Yang WC. Far-infrared therapy: a novel treatment to improve access blood flow and unassisted patency of arteriovenous fistula in hemodialysis patients. J Am Soc Nephrol. 2007;18(3):985–992. doi: 10.1681/ASN.2006050534.
    1. Lai CC, Fang HC, Mar GY, Liou JC, Tseng CJ, Liu CP. Post-angioplasty far infrared radiation therapy improves 1-year angioplasty-free hemodialysis access patency of recurrent obstructive lesions. Eur J Vasc Endovasc Surg. 2013;46(6):726–732. doi: 10.1016/j.ejvs.2013.09.018.
    1. Choi SJ, Cho EH, Jo HM, Min C, Ji YS, Park MY, Kim JK, Hwang SD. Clinical utility of far-infrared therapy for improvement of vascular access blood flow and pain control in hemodialysis patients. Kidney Res Clin Pract. 2016;35(1):35–41. doi: 10.1016/j.krcp.2015.12.001.
    1. Heaf JG, Jespersen B. Dansk nefrologisk selskabs landsregister. Ugeskr Laeger. 2012;174(42):2557.
    1. Lok CE, Huber TS, Lee T, Shenoy S, Yevzlin AS, Abreo K, Allon M, Asif A, Astor BC, Glickman MH, Graham J, Moist LM, Rajan DK, Roberts C, Vachharajani TJ, Valentini RP. KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update. Am J Kidney Dis. 2020;75(4):S1–164. doi: 10.1053/j.ajkd.2019.12.001.
    1. Brahmbhatt A, Remuzzi A, Franzoni M, Misra S. The molecular mechanisms of hemodialysis vascular access failure. Kidney Int. 2016;89(2):303–316. doi: 10.1016/j.kint.2015.12.019.
    1. Siddiqui MA, Ashraff S, Carline T. Maturation of arteriovenous fistula: Analysis of key factors Kidney Res Clin Pract Actions 2017;36(4):318-28.
    1. Wilmink et al. Is early cannulation of an arteriovenous fistula associated with early failure of the fistula_.pdf. J Vasc Access. 2017;18(Suppl. 1):92-97.
    1. Lee T, Misra S. New insights into dialysis vascular access: molecular targets in arteriovenous fistula and arteriovenous graft failure and their potential to improve vascular access outcomes. Clin J Am Soc Nephrol. 2016;11(8):1504–1512. doi: 10.2215/CJN.02030216.
    1. Tanner NC, Da Silva A. Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts. Cochrane Database Syst Rev. 2015;2015(7). .
    1. McGrogan DG, Stringer S, Cockwell P, Jesky M, Ferro C, Maxwell AP, et al. Arterial stiffness alone does not explain arteriovenous fistula outcomes. J Vasc Access. 2018;19(1):63–68. doi: 10.5301/jva.5000791.
    1. MacRae JM, Ahmed S, Hemmelgarn B, Sun Y, Martin BJ, Roifman I, et al. Role of vascular function in predicting arteriovenous fistula outcomes: An observational pilot study. Can J Kidney Heal Dis. 2015;2(1):1–8.
    1. Allon M, Greene T, Dember LM, Vita JA, Cheung AK, Hamburg NM, Imrey PB, Kaufman JS, Robbin ML, Shiu YT, Terry CM, Umphrey HR, Feldman HI, the Hemodialysis Fistula Maturation Study Group Association between preoperative vascular function and postoperative arteriovenous fistula development. J Am Soc Nephrol. 2016;27(12):3788–3795. doi: 10.1681/ASN.2015020141.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner